South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement
PR90470
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology
DAEJEON, South Korea and CASTRES, France, July 6, 2021 29 /PRNewswire=KYODO JBN/ --
The South Korean biotech company Y-Biologics and the French pharmaceutical
group Pierre Fabre have entered into a license agreement granting worldwide
exclusive rights to Pierre Fabre to develop and commercialize a family of human
antibodies generated through the phage display human antibody Ymax (R) - ABL
library owned by Y-Biologics.
These antibodies have been functionally validated by the Pierre Fabre R&D teams
for their specific properties on a pivotal immuno-oncology target acting on the
tumoral microenvironment. Pierre Fabre intends to select a new therapeutic
candidate in immuno-oncology for further developments.
This licensing agreement results from the strong and now proven complementarity
between the two companies who have been collaborating since 2018. The final
objective pursued by Y-Biologics and Pierre Fabre is to provide patients with
innovative drugs to target refractory or relapsing cancer, taking advantage of
the immune infiltrate to inhibit the growth of tumor cells.
This new milestone reached by the two companies reveals the effectiveness of
the scientific means put in place by Y-Biologics, associated with the high
expertise of Pierre Fabre in oncology.
Young Woo Park, CEO of Y-Biologics, stated: “We are very pleased to sign our
first license agreement with Pierre Fabre. The collaboration between
Y-Biologics and Pierre Fabre which is being conducted based on mutual trust, is
expected to further advance the development of innovative immuno-oncology
therapeutics targeting the tumor microenvironment.”
"Since the beginning of our partnership, the collaboration with Y-Biologics has
been very efficient and fruitful. Their library has allowed us to identify a
family of human antibodies against a promising target defined by our
researchers at our dedicated Center of Immunology. This new exciting license
agreement will allow us to further support the development of this therapy for
the benefit of patients," added Nathalie Corvaïa, Head of Immuno-Oncology
Research, Center of Immunology Pierre Fabre (CIPF).
Further information about Y-Biologics can be found at
http://ybiologics.com/eng/main/
Further information about Pierre Fabre can be found at www.pierre-fabre.com /
@PierreFabre.
Logo -
https://mma.prnewswire.com/media/1557487/Y_Biologics_Pierre_Fabre_Logo.jpg
Pierre Fabre:
Anne Kerveillant, Communication Manager
anne.kerveillant@pierre-fabre.com
Y-Biologics:
Dong-Ock Chang
dochang@ybiologics.com
Joint source: Pierre Fabre and Y-Biologics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。